Kim Minsup, Wei Jun-Dong, Harmalkar Dipesh S, Goo Ja-Il, Lee Kyeong, Choi Yongseok, Kim Jae-Hong, Cho Art E
inCerebro Co., Ltd. Drug Discovery Institute, Seoul Technopark, 232 Gongneung-ro, Nowon-gu, Seoul 01811, Korea.
Department of Biochemistry, Medical College, Taizhou University, Taizhou, 318000, Zhejjang, China.
ACS Med Chem Lett. 2020 Jul 14;11(8):1529-1534. doi: 10.1021/acsmedchemlett.0c00065. eCollection 2020 Aug 13.
G protein-coupled receptors (GPCRs) have always been important drug targets in the pharmaceutical industry. One major question for the current GPCR drug discovery is how drugs have distinct efficacies at the same GPCR target. Related to this question, we studied how different ligands can have disparate efficacies at Leukotriene B receptor (BLT2). By using molecular modeling studies, we predicted that Tyr271 located at TM6 of BLT2 performs as a key trigger for its activation and verified the prediction by site-directed mutagenesis, chemotactic motility studies, which included a chemical derivative of agonist CAY10583. We further identified Asn275 located at TM6 as a weak activation trigger in BLT2 and performed double mutation studies to confirm our computational results. Our results provide strong evidence for the exact mechanism of ligand efficacy at BLT2.
G蛋白偶联受体(GPCRs)一直是制药行业重要的药物靶点。当前GPCR药物研发面临的一个主要问题是,药物如何在同一GPCR靶点上具有不同的药效。针对这个问题,我们研究了不同配体在白三烯B受体(BLT2)上如何产生不同的药效。通过分子模拟研究,我们预测位于BLT2第6跨膜区(TM6)的酪氨酸271(Tyr271)是其激活的关键触发因素,并通过定点诱变、趋化运动性研究(包括激动剂CAY10583的一种化学衍生物)验证了这一预测。我们进一步确定位于TM6的天冬酰胺275(Asn275)是BLT2中的一个弱激活触发因素,并进行了双突变研究以证实我们的计算结果。我们的结果为BLT2上配体药效的确切机制提供了有力证据。